Skip to main content
. 2020 Aug 6;5(15):e134290. doi: 10.1172/jci.insight.134290

Figure 1. Therapeutic and transcriptional response of TNBC PDX models to standard chemotherapy or standard chemotherapy with MEK inhibition.

Figure 1

(A) Representative Western blot of untreated tumors from PDX models. (B) Schematic for treatment of PDX models. (C) Tumor growth curves for PDX models. (n = 5–10 per condition.) AC, adriamycin (doxorubicin) and cyclophosphamide; T, taxane (docetaxel). (D) Final tumor volumes at 28 days. (n = 5–10 per condition.) P value represents 2-sample 2-tailed t test. (E) Western blot of representative treated tumors from C and D. ****P < 0.0001.